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Abstract The intricate regulation of Spot 14 expression in rat 
lipogenic tissues has provided a useful tool in studying nutritional 
and hormonal factors involved in transcription. To gain insight 
into its function and its possible involvement in human lipid 
disorders, we cloned human and mouse Spot 14 genes that shared 
with the rat gene a strong homology concerning the deduced 
amino acid sequence (81 and 94%, respectively) as well as the 
promoter region. The mouse promoter was characterized by 
transfection studies, while quantitative RT-PCR and in situ 
hybridization experiments showed that Spot 14 is expressed in 
human liver and, at a high level, in multiple symmetric 
lipomatosis nodules. 
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1. Introduction 
Since its initial characterization in rat liver as a thyroid 
hormone responsive gene [1], Spot 14 has been the focus of 
interest of many investigators because of the intricate regula-
tion of its expression. Mainly expressed in tissues that synthe-
size triglycerides, the mRNA coding for Spot 14 has been 
shown to be increased in rat liver by insulin [2], dietary car-
bohydrates [3], glucose in hepatocyte culture medium [4], as 
well as thyroid hormone. In contrast, dietary fats [5] and 
polyunsaturated fatty acids [6], have been shown to decrease 
the amount of Spot 14 mRNA, while an elevated level of 
cAMP acts as a dominant negative factor [2]. In addition, 
liver-specific factors [7,8] or chromatin organization of the 
gene [9] have been shown to contribute to the regulation of 
its expression. The promoter region of rat Spot 14 has been 
previously cloned [1] and several sequences involved in the 
regulation of the transcription have been described such as 
thyroid hormone response elements (TRE) [10] or carbohy-
drate response element (CHORE) [11]. However, several sub-
sequent studies have indicated that the mechanisms of inter-
actions between the CHORE and the TREs are very complex 
[12,13]. 
Spot 14 expression has also been studied in adipose tissues 
(white as well as brown). In these tissues, insulin and cAMP 
[14], retinoic acid [15] and adipocyte-specific factors [16] 
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seemed to play crucial roles in the control of the expression 
of the gene. 
Despite this impressive wealth of studies, little is known 
about the function of the protein whose localization has 
been reported to be nuclear [17]. Nevertheless, the regulation 
of its expression, although slightly different in liver and in 
adipose tissues, featured Spot 14 as playing an important 
role in lipogenesis. To gain further insight into the regulation 
of its expression in the course of adipose differentiation proc-
ess and thus the possible role of the protein, it seemed inter-
esting to clone the mouse gene. Indeed, established adipocyte 
cell lines are derived from this animal species and moreover, 
the mouse gene is a requisite tool in transgenic studies. Simi-
larly, cloning of the human homologue appears as a first step 
in the search for a possible involvement of Spot 14 in patho-
logical processes related to lipid metabolism disorders. We 
present here the characterization of the human and mouse 
genes and show that Spot 14 is highly conserved between 
rodents and humans as well as being expressed in human 
lipogenic tissues such as liver and adipocytes. 
2. Materials and methods 
2.1. Cloning of mouse and human Spot 14 genes 
A Balb c genomic library constructed in EMBL3 phage (Clontech) 
was screened according to standard protocol [18] with a Pstl-TaqI 789 
bp rat genomic fragment that contains the whole coding sequence [19] 
as a probe. At every round of the screening procedure, each plaque 
giving a hybridization positive signal was checked for the presence of 
Spot 14 coding sequence by PCR amplification using a set of primers 
designed from the rat sequence. This protocol allowed us to reduce 
the time required for the isolation of the two Spot 14 containing 
clones (4011 and 4021) that were finally selected. Clone 4011 was 
digested by Sacl restriction enzyme and subcloned into the corre-
sponding site of pBluescript (Stratagene) plasmid. One of these sub-
clones, pM600, was shown by PCR procedure to contain the whole 
coding region. The restriction map of pM600 allowed us to sequence 
completely a 2044 bp fragment contained between a PstI and an Eael 
restriction site. 
Considering the strong homology between mouse and rat coding 
sequences, we used a set of primers able to amplify both mouse and 
rat coding sequences. RT-PCR amplification from a human hepatic 
cDNA pool was carried out according to a previous report [20]. The 
amplified fragment was then sequenced and used to design two other 
sets of primers for walking upstream and downstream in uncloned 
human genomic DNA using a nested long distance PCR protocol 
(DNA walking kit, Clontech). Both upstream (about 800 bp) and 
downstream (about 2600 bp) amplified fragments were subcloned 
into PCR II vector (Invitrogen) and finally sequenced. 
2.2. Study of the expression of the human and mouse genes 
Two samples of human liver tissues (one of them producing exten-
sive steatosis) in the vicinity of surgically removed hepatocarcinoma 
nodules as well as a sample of lipomatous nodule from the scapular 
region of a patient suffering from Launois-Bensaude's disease (multi-
ple symmetric lipomatosis), were studied, with the informed consent 
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of each patient. Samples were immediately frozen in liquid nitrogen 
and then stored at —80°C until use. HepG2 cells (human hepatoma 
cell line), FAO cells (rat hepatoma cells) and Huvec (human umbilical 
vein endothelial cells) were cultured in 35 mm diameter culture dishes 
with DMEM supplemented with appropriate antibiotics and 10% fetal 
calf serum according to standard protocols. Ob 17 cells, which derived 
from adult mouse periepididymal white adipose tissue [21], were cul-
tured in 60 mm diameter dishes under the same conditions. After 
complete differentiation of the adipocyte cells, calf serum was with-
drawn for 24 h and dexamethasone or retinoic acid was added. RNA 
extraction was performed according to a microscale method [22]. 
Amounts of mRNA encoding human and mouse Spot 14 proteins 
were assayed using a quantitative multistandard RT-PCR method 
that takes advantage of both Spot 14 and ß-actin sequence conserva-
tion between animal species [20]. This protocol allowed us to normal-
ize the amounts of Spot 14 mRNA with regard to that of ß-actin 
mRNA in each sample. Briefly, total RNA samples extracted from 
human tissues or mouse cells were mixed with a constant amount of 
total RNA prepared from rat liver which brought both competitive 
rat ß-actin and Spot 14 sequences and thus acted as an multistandard 
source. All RNA preparations were incubated in the presence of 
RNase-free DNase (Promega) in order to avoid amplification from 
possible contamination by genomic DNA. The mixture was reverse-
transcribed using hexa random primers. Separate PCRs for Spot 14 
and for ß-actin amplification were then undertaken with oligonucleo-
tide primers that are able to hybridize with rat, mouse and human 
sequences with the same efficiency. For Spot 14 amplification, the 
direct primer, SHR77, extended from nucleotide 99 to 122 and the 
reverse primer, SHR371, from nucleotide 402 to 379, according to the 
rat sequence [1]. For ß-actin amplification, the direct primer (ACT53) 
extended from nucleotide 558 to 579 and the reverse primer (ACT33) 
from nucleotide 1126 to 1100, according to the human sequence [23]. 
Each amplification product was then distinguished by restriction site 
polymorphism: the human and mouse Spot 14 products were digested 
by Pvull into two fragments (245 and 47 bp for human and 257 and 
47 bp for mouse), while the rat product remained uncut. A similar 
difference in pattern of restriction sites was used to differentiate ß-
actin products: a single Pvull restriction site (producing 475 and 94 
bp fragments) was present in rat, but not in human or mouse. Quan-
tification of each amplification product was performed after electro-
phoresis and analysis of ethidium bromide stained gels. In each hu-
man sample, the ratio of actual moles of Spot 14 mRNA vs. ß-actin 
mRNA (sh/ah) is equal to RXc, where R is the ratio of human Spot 
14 product vs. rat Spot 14 product, normalized with regard to ß-actin 
and c is the ratio of the actual amounts of Spot 14 mRNA vs. ß-actin 
mRNA in the rat multistandard liver preparation [20]. The same 
quantification process was applied to mouse samples. 
In order to perform in situ hybridization (ISH), human Spot 14 
PCR product from genomic amplification was subcloned into the 
Smal site of the polylinker of pBluescript (Stratagene) and sequenced 
to check for its orientation. Two PCRs were performed using this 
recombinant plasmid as a template and either T3 and SHR77 or T7 
and SHR371 as primers. Products were purified from agarose gels 
after electrophoresis and used as matrices in an in vitro transcription 
protocol: 100 ng of each amplification product were used as matrices 
to produce 11-UTP-digoxigenin labeled sense and antisense cRNA 
probes in the presence of T3 or 77 RNA polymerase (Promega) re-
spectively. Cryostat serial sections of human liver samples were fixed 
in paraformaldehyde, dehydrated, and stored at —80°C before being 
used in an ISH protocol with 10 ul of each probe at 50 ng/ul, as 
extensively described in a previous report [24]. In each experiment, 
controls included sections incubated with the sense probe, sections 
preincubated in the presence of RNase A (10 ug/ml) a n d sections 
without any probe. No significant labeling could be seen in these 
controls. 
cells, two promoter sequences (—220/+19 in the case of pSAluc and 
—110/+19 in the case of pKlluc) were ligated in front of luciferase 
coding sequence in pGL2 vector (Promega). Three culture dishes of 
FAO cells (derived from rat hepatoma), or preadipocyte Ob 17 cells or 
HepG2 cells were transfected with CsCl-purified DNA preparations of 
Spot 14 promoter luciferase expression plasmids, using lipofectamine 
(Gibco-BRL). Ob 17 cells (60 mm diameter dishes) were transfected 
with 5 (ig DNA, while HepG2 and FAO cells (35 mm diameter dishes) 
were transfected with 2 ug DNA. In both cases, the DNA/lipofecta-
mine ratio was 1:5 (w/w). Cells were maintained in the presence of 
this mixture for 18 h, then washed and the luciferase activity was 
assayed 24 h later. As controls, pSV401uc and Basic (no promoter 
sequence) plasmids were transfected in parallel experiments. Lucifer-
ase activity was normalized in each dish according to the protein 
content. 
3. Results 
During the screening of the mouse genomic library, the use 
of a PCR amplification step greatly reduced the time neces-
sary to clone the Spot 14 gene. We screened 0.5 X 106 clones 
and three hybridization rounds were necessary to purify two 
clones (4011 and 4021) which were shown to contain the cod-
ing sequence. Mouse clone pM600 presented an open reading 
frame of 450 bp whose translation led to a putative protein 
highly similar to that of the rat (see Fig. la). Since mouse and 
rat coding sequences shared a high degree of homology, we 
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2.3. Study of mouse promoter region 
Primer extension experiments were undertaken using a 5' radiola-
beled 46-mer oligonucleotide complementary to the mouse sequence 
that was hybridized against 50 ug of liver or adipocyte total RNA. 
Reverse transcription from annealed primer was achieved with 200 U 
Moloney Murine Leukemia Virus reverse transcriptase (Gibco-BRL). 
The length of the extended primer was evaluated by electrophoresis in 
a sequencing gel (5% polyacrylamide, 8 M urea). 
In order to test the functionality of promoter sequence in various 
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Fig. 1. (a) Alignment of human, mouse and rat Spot 14 amino acid 
sequences. The amino acids which are identical in human, mouse 
and rat Spot 14 are in bold. Non-conserved amino acids are under-
lined. (b) Amino acid sequence of human Spot 14 and comparison 
with zebrafish G12. Amino acids which are identical in both pro-
teins are indicated by vertical lines. Conservative substitutions are 
dotted. 
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Fig. 2. Nucleotide sequence of human and mouse Spot 14 gene bas-
al promoter regions. The TAGAA sequence is underlined. Relevant 
motifs CAAT box (-), MLTF (X), and NF1 (+) are shown. Con-
served nucleotides are indicated by vertical lines. 
hypothesized that a set of primers designed from these se-
quences could amplify the human homologue sequence from 
a supposed highly expressing tissue such as liver. This first 
RT-PCR allowed us to amplify a 300 bp fragment that was 
used to design two sets of nested primers and then to screen 
an uncloned human genomic DNA. The 800 bp upstream 
fragment and the 2.6 kb downstream fragment were sub-
cloned and then sequenced. Obviously, the open reading 
frame deduced from these sequences was not interrupted by 
any intron. This allowed us to design another set of primers in 
order to amplify a 641 bp fragment which contained the sup-
posed whole coding sequence. Three amplified products from 
genomic DNA of unrelated individuals produced the same 
sequence and confirmed that deduced from the sequencing 
of the library clones. The human 438 bp open reading frame 
was translated into a putative protein similar to those of 
mouse and rat (Fig. la). The rat Spot 14 amino acid sequence 
has recently been related to an acidic protein which is specif-
ically expressed during zebrafish (Brachydanio rerio) develop-
ment [25]. The amino acid sequence of this protein and its 
homology with the human Spot 14 sequence are shown in 
Fig. lb. 
Mouse and human promoters were strongly similar (Fig. 2). 
They also presented a strong homology with the formerly 
reported rat promoter sequence [1]. Interestingly, the TAGAA 
motif which is considered as the rat TATAA box element was 
found to be 100% similar in both mouse and human se-
quences. Analysis of the consensus signal sequences of pro-
moters showed several potential regulatory elements. In Fig. 
2, we marked some elements that can be considered as rele-
vant: CTF/NF1 [26]; CCAAT box and MLTF [27]. It should 
be noted that the mouse —1370/—1401 sequence presents a 
strong homology (93%) with the rat —1457/—1448 fragment 
shown to contain the carbohydrate response element. Never-
theless, the mouse core motif itself differs from its rat counter-
part by 1 nucleotide. 
The expression of Spot 14 is well-documented in established 
cell lines such as 3T3-L1 [28,29] and 3T3-F442A [15,30]. We 
show here that Ob 17 cells also express this gene and this 
expression is restrained to the fully differentiated cells. The 
level of mRNA increased when cells were incubated in the 
presence of 1 uM retinoic acid for 4 h or 100 nM dexametha-
sone for 72 h (Fig. 3a). Primer extension experiments are 
displayed in Fig. 3b. The extended strand from mRNA ex-
tracted from mouse adipocytes is of the same length as that 
obtained from rat liver mRNA and may be considered as 5'-
complementary strands of mRNA whose transcription is un-
der the control of the TAGAA motif. Furthermore, the mouse 
sequence, although it lacked a canonical TATAA box, pro-
duced an efficient promoter activity (Fig. 3c). This activity was 
stronger in mouse preadipocytes than in rat FAO cells or 
human HepG2 cells, when normalized with respect to 
pSV40 activities. Both pSAluc and pKlluc plasmids were 
equally efficient in Ob 17 cells, but obviously weaker in human 
or rat cells. Furthermore, pKlluc turned out to be weaker 
than pSAluc in both hepatoma cell lines. 
Human liver samples, HepG2 cell line and the Launois-
Bensaude's disease nodule expressed the Spot 14 specific 
mRNA. When assayed using a quantitative RT-PCR method, 
the amount of human mRNA coding for Spot 14 with regard 
to cellular ß-actin mRNA content, was markedly different 
from one sample to another (Fig. 4a). The amount of 
Spot 14 mRNA was higher in the lipomatous tissue 
(20X10 - 3 mol of Spot 14 mRNA per mol of ß-actin 
mRNA) than in control liver (14xl0~3) , while it seemed 
weakly expressed in the steatosic liver (1.2 X 10~3) and in 
HepG2 cell line (0.4 X 10 -3). In contrast, Huvec cell line and 
primary cultures of lipomatous undifferentiated adipocytes 
did not express Spot 14 mRNA (data not shown). 
ISH experiments in liver sections confirmed these results 
and specified the cellular localization of Spot 14 mRNA 
(Fig. 4b). Blue-brown deposits within hepatocyte cytoplasm 
were present in control liver, while they were not detected in 
steatosic liver. Other liver cells remained unlabeled. 
4. Discussion 
Cloning of mouse and human genes allowed us to demon-
strate that both of them share a similar organization, which is 
also similar to that of the rat, since the whole coding sequence 
is not interrupted by any intron. The three genes also display 
a high degree of conservation of their promoter sequences. 
Efficiency of the mouse promoter was tested in three different 
cell types: rat and human hepatoma cells (FAO and HepG2 
cell lines, respectively) and Obl7 cells at the preadipocyte 
stage. When cloned in front of the coding sequence of lucifer-
ase, the mouse sequence was able to direct the expression of 
this gene in mouse preadipocytes as well as in rat and human 
hepatoma cells, although obviously this expression was weak-
er in these two last cases. Slight differences observed in se-
quences could explain the greater efficiency observed in mouse 
derived cells. It is also noteworthy that, if 3T3-L1 and 3T3-
F442A cell lines are known to express actively the Spot 14 
gene in culture, this expression is strictly restrained to cells 
fully differentiated into adipocytes [15,29]. Inasmuch as we 
revealed, in Ob 17 preadipocytes, a marked luciferase activity 
when the expression of this gene is under the control of the 
proximal promoter sequence, it would be interesting to search 
for the existence of a silencing region - not present in our 
J.-P. Grillasca et al.lFEBS Letters 401 (1997) 38-42 41 
constructions - able to repress the basal promoter at the pre-
adipocyte stage. 
Both rodent sequences are 150 amino acids long, while the 
human sequence is shorter by only 4 amino acids. The de-
duced amino acid sequences of mouse and rat proteins share a 
94% homology. The human sequence presents 83 and 81% 
homology with regard to mouse and rat sequences, respec-
Fig. 3. (a) Expression of Spot 14 in Obl7 cells (fully differentiated 
adipocytes). Spot 14 mRNA levels were assayed by quantitative 
RT-PCR. Cells were incubated in the presence of agents or vehicles 
as indicated. Each data value is the mean of the values obtained 
from three independent experiments and bars indicate ± S.E.M. (b) 
Denaturing gel electrophoresis of 5'-extended strands using Spot 14 
specific primer. Total RNA from rat liver or mouse Ob 17 cells was 
hybridized against a radiolabeled 46-mer oligonucleotide at high 
(lanes 2,5) or low (lanes 3,6) stringency before reverse transcription. 
Lanes 1 and 4 refer to control run of labeled primer alone. Arrows 
indicate the size (in nt) of denatured strands, (c) Luciferase activity 
in various cell lines transfected with Spot 14 promoter-luciferase chi-
meric genes. 100% luciferase activity in cells transfected with pSV40-
luciferase control plasmids corresponds to 16±1.5X103, 
5.6±0.5X103 and 13±1 .2x l0 3 arbitrary units in Obl7, FAO and 
HepG2 hepatoma cells, respectively. The values shown are the mean 
of the values obtained from 3 independent transfections and bars in-
dicate ± S.E.M. 
tively. In a recent study, a 'gastrulation-specific' protein, 
named G12, cloned from Zebrafish, has been shown to share 
33% homology with rat Spot 14 protein [25]. Conserved ami-
no acids are regularly spaced along the primary structures and 
several clusters are mainly located at the N-terminal moiety of 
the proteins (see Fig. lb). The highest degree of similarity 
(74%) is present in a region extending from amino acid 24 
to 42 (Spot 14 sequence), which suggests that this region 
may fulfill a common function in these proteins. When 
matched to other sequences in the Genbank non- redundant 
database library, this 'spot-box' was present in some pre-
viously reported human sequences, "T68776, *T73661 and 
*R13768. The first two cloned from adult hepatic tissue li-
brary are obviously partial sequences of Spot 14. In contrast, 
*R13768, cloned from infant brain tissue library, encodes a 
putative peptide which is 100% similar to zebrafish G12 in its 
N-terminal part. 
The Spot 14 amino acid sequence has never been related to 
any other known protein, but the recent cloning of the zebra-
fish G12-mRNA could help in elucidating its function. Spot 
14 expression is known to be rapidly induced in response to 
agents such as thyroid hormone [31]. In addition, the protein 
has been shown to have a nuclear localization [17] and to be 
necessary in liver transcription process of proteins involved in 
lipogenesis [32]. Similarly, the G12 gene is expressed, for a 
short period, in the cells that will produce the enveloping 
layer. 
We show here that mouse and human Spot 14 genes encode 
putative proteins whose pi values are 4.76 and 4.65, respec-
tively. Rat protein presents a similar p / (4.62). It should be 
noted that most of the amino acid variations observed be-
tween rodent and human proteins, are located from amino 
acid 87 to 114 (rodent sequence) where, in the human se-
quence, a 4 amino acid gap as well as 8 substitutions can be 
found. Nevertheless, despite this relatively weak homology, 
this short region remains highly acidic (14 carboxyl-carrying 
residues/28 in rodents vs. 11/24 in human). Interestingly, G12 
is also a small protein (152 amino acids), whose p/(4.94) is as 
low as that of Spot 14. In addition, G12 displays an acidic 
region similar to that of Spot 14 (from amino acid 95 to 114). 
Predictive analyses of the secondary structures [33] of these 
acidic regions reveal a highly probable amphipathic oe-helix 
organization. Therefore, their low pi as well as the existence 
of this highly acidic and amphipathic region is certainly an 
important feature of Spot 14 and zebrafish G12. Indeed, this 
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Fig. 4. (a) Quantification of Spot 14 mRNA with regard to ß-actin 
content in human tissues. A mixture of total RNA from rat and hu-
man tissues was reverse transcribed and amplified separately for 
Spot 14 detection (upper gel) and for ß-actin detection (lower gel). 
MultiStandard was rat liver total RNA. Human total RNA was ex-
tracted from Launois-Bensaude nodule (lane 2), HepG2 cells (lane 
3), steatosic human liver (lane 4) and human liver sample peripheral 
to hepatocarcinoma (lane 5). Lanes 1,6: control samples (without 
reverse transcribed RNA). When digested with Pvull restriction en-
zyme, human Spot 14 amplification product produced a 245 bp 
fragment, while rat product remained uncut (292 bp). When di-
gested by the same enzyme, human ß-actin remained uncut (469 
bp), while rat product displayed a 475 bp fragment, (b) In situ hy-
bridization of human Spot 14 mRNA in liver tissues (magnificatio-
nX320). (1) Hepatic tissue in the vicinity of hepatocarcinoma, hy-
bridized with antisense probe. (2) Tissue section serial to previous 
one, hybridized with sense probe. (3) Steatosic tissue in the vicinity 
of hepatocarcinoma, hybridized with antisense probe. 
brings to mind the secondary structure of some transcription 
factors such as G C N 4 [34] or G A L 4 [35]. Nevertheless, 
further studies will be necessary to specify the role that Spot 
14 could play in a transcription process. Homology with G12 
protein could be a helpful tool in this work. 
Taking into account the regulation of Spot 14 expression in 
rodent liver and adipose tissues, expression of the human 
homologue gene was expected in lipogenic tissues. Indeed, 
we found that Spot 14 was expressed in hepatocytes, although 
at a lower level in hepatocytes from steatosic liver, in which 
lipid metabolism is deeply disturbed. Similarly, a high level of 
Spot 14 m R N A was demonstrated in nodules from a patient 
suffering from Launois-Bensaude's disease. This could be re-
lated to resistance to catecholamines described in this disease 
[36] and to the fact that c A M P is known to strongly decrease 
Spot 14 expression, at least in rodents tissues. Fur ther inves-
tigations on lipid metabolism disorders in humans would be 
interesting to specify Spot 14 involvement in lipid metabolism. 
Acknowledgements: J.P.G. is a recipient of Nestlé-France award. 
H.K. was beneficiary of CIFRE grant in collaboration with Labora-
toire Alphabio, Marseilles. 
[19 
[20; 
[21 
[22 
[23; 
[24; 
[25; 
pe; 
[27 
[28; 
[29 
[30; 
[31 
[32 
[33 
[34] 
[35 
[36 
Liaw, C.W. and Towle, H.C. (1984) J. Biol. Chem. 259, 7253-
7260. 
Jump, D.B., Bell, A., Lepar, G. and Hu, D. (1990) Mol. Endo-
crinol. 4, 1655-1660. 
Towle, H.C. and Mariash, C.N. (1986) Fed. Proc. 45, 2406-2411. 
Goto, Y. and Mariash, C.N. (1992) Diabetes 41, 339-346. 
Clarke, S.D., Armstrong, M.K. and Jump, D.B. (1990) J. Nutr. 
120, 225-231. 
Jump, D.B., Clarke, S.D., MacDougald, O. and Thelen, A. 
(1993) Proc. Nati. Acad. Sei. USA 90, 8454-8458. 
Deschamps, B.J., Lawless, D.E., Carr, F.E. and Wong, N.C. 
(1992) J. Biol. Chem. 267, 25167-25173. 
Wong, N . C , Raymond, J. and Carr, F.E. (1993) J. Biol. Chem. 
268, 19431-19435. 
Jump, D.B., Bell, A. and Santiago, V. (1990) J. Biol. Chem. 265, 
3474-3478. 
Zilz, N.D., Murray, M.B. and Towle, H.C. (1990) J. Biol. Chem. 
265, 8136-8143. 
Shih, H.M. and Towle, H.C. (1992) J. Biol. Chem. 267, 13222-
13228. 
Sudo, Y., Goto, Y. and Mariash, C.N. (1993) Endocrinology 
133, 1221-1229. 
Sudo, Y. and Mariash, C.N. (1994) Endocrinology 134, 2532-
2540. 
Perez Castillo, A., Hernandez, A., Pipaon, C , Santos, A. and 
Obregon, M.J. (1993) Endocrinology 133, 545-552. 
Lepar, G.J. and Jump, D.B. (1992) Mol. Cell. Endocrinol. 84, 
65-72. 
MacDougald, O.A. and Jump, D.B. (1992) Biochem. Biophys. 
Res. Commun. 188, 470^176. 
Kinlaw, W.B., Tron, P. and Friedmann, A.S. (1992) Endocrinol-
ogy 131, 3120-3122. 
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular 
Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory 
Press, Cold Spring Harbor, NY. 
Planells, R., Peyrol, N., De Groot, L.J., Henry, M., Cartouzou, 
G. and Torresani, J. (1991) Gene 99, 205-209. 
Khiri, H., Reynier, P., Peyrol, N., Lerique, B., Torresani, J. and 
Planells, R. (1996) Mol. Cell. Probes 10, 201-211. 
Negrel, R., Grimaldi, P. and Ailhaud, G. (1978) Proc. Nati. 
Acad. Sei. USA 75, 6054-6058. 
Chomczynsky, P. and Sacchi, N. (1987) Anal. Biochem. 162, 
156-159. 
Ponte, P., Ng, S.Y., Engel, J., Gunning, P. and Kedes, L. (1984) 
Nucl. Acids Res. 12, 1687-1696. 
Gastaldi, M., Massacrier, A., Planells, R., Robaglia-Schlupp, A., 
Portal-Bartolomei, I., Bourliere, M., Quilici, F., Fiteni, J., Maz-
zella, E. and Cau, P. (1995) J. Hepatol. 23, 509-518. 
Conway, G. (1995) Mech. Dev. 52, 383-391. 
Jones K, A., Kadonaga J, T., Rosenfeld P, J., Kelly T, J. and 
Tjian, R. (1987) Cell 48, 79-89. 
Carthew R, W., Chodosh L, A. and Sharp P, A. (1985) Cell 43, 
439^448. 
Hausdorf, S., Clement, J. and Loos, U. (1988) Horm. Metab. 
Res. 20, 723-724. 
Loos, U., Clement, J., Behr, M. and Fischer, S. (1991) Mol. Cell. 
Endocrinol. 75, R7-11. 
Lepar, G.J. and Jump, D.B. (1989) Mol. Endocrinol. 3, 1207-
1214. 
Jump, D.B., Narayan, P., Towle, H. and Oppenheimer, J.H. 
(1984) J. Biol. Chem. 259, 2789-2797. 
Kinlaw, W.B., Church, J.L., Harmon, J. and Mariash, C.N. 
(1995) J. Biol. Chem. 270, 16615-16618. 
Rost, B. and Sander, C. (1994) Proteins 19, 55-72. 
Hope, I.A., Mahadevan, S. and Struhl, K. (1988) Nature 333, 
635-640. 
Ma, J. and Ptashne, M. (1987) Cell 48, 847-853. 
Enzi, G., Inelmen, E.M., Baritussio, A., Dorigo, P., Prosdocimi, 
M. and Mazzoleni, F. (1977) J. Clin. Invest. 60, 1221-1229. 
